1.Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2020; 5(8):739-752.
2.Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015; 1:15080.
3.Diehl AM, Farpour-Lambert NJ, Zhao L, Tilg H. Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease. Nat Metab. 2019; 1(11):1027-1029.
4.Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020; 71(5):1851-1864.
5.Wang Y, Fan S, Yang M, Shi G, Hu S, Yin D, Zhang Y, Xu F. Evaluation of the mechanism of Danggui-Shaoyao-San in regulating the metabolome of nephrotic syndrome based on urinary metabonomics and bioinformatics approaches. J Ethnopharmacol. 2020; 261:113020.
6.Chen Y, Xia J, Liu D, Liu X, Zhang T, George DB, Lizhou L, You Y, Xie Y, Gong Y, et al. Mechanism of Danggui Shanyao San's Action on Alzheimer's Disease: Review of Research Advances. Chinese Journal of Experimental Traditional Medical Formulae. 2021:1-7.
7.Yue X. Effects and Mechanism of Danggui-Dhaoyao-Dan on Nephrotic Syndrome Based on the Path of AVP-V2R-AQP2.: Anhui University of Chinese Medicine; 2015.
8.Peng C. Clinical Observation of Danggui Shaoyao San combined with Acupuncture in the Treatment of Nonalcoholic Fatty Liver Disease( Liver Depression and Spleen Deficiency Type).: Hubei University of Chinese Medicine; 2020.
9.Zhang L. Paeoniflorin Protects against Nonalcoholic Fatty Liver Disease Induced by a High-fat Diet in Mice.: Wuhan University; 2016.
10.Biao Y, Chu X, Chenxu L, Han X, Zhang Y, Han Y, Zhang Y. Study on Protective Mechanism of Danggui Shaoyao Powder on Mechanical Barrier of Intestinal Mucosa in Rats with Nonalcoholic Fatty Liver Disease. Chinese Journal of Information on TCM. 2021:1-7.
11.Liu H, Wang J, Zhou W, Wang Y, Yang L. Systems approaches and polypharmacology for drug discovery from herbal medicines: An example using licorice. J Ethnopharmacol. 2013; 146(3):773-793.
12.Jiao X, Jin X, Ma Y, Yang Y, Li J, Liang L, Liu R, Li Z. A comprehensive application: Molecular docking and network pharmacology for the prediction of bioactive constituents and elucidation of mechanisms of action in component-based Chinese medicine. Comput Biol Chem. 2021; 90:107402.
13.He D, Huang J, Zhang Z, Du Q, Peng W, Yu R, Zhang S, Zhang S, Qin Y. A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus. 2019; Volume 13:3989-4005.
14.Gan D, Xu X, Chen D, Feng P, Xu Z. Network Pharmacology-Based Pharmacological Mechanism of the Chinese Medicine Rhizoma drynariae Against Osteoporosis. Med Sci Monitor. 2019; 25:5700-5716.
15.Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014; 6:13.
16.Liu X, Ouyang S, Yu B, Liu Y, Huang K, Gong J, Zheng S, Li Z, Li H, Jiang H. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res. 2010; 38(suppl_2):W609-W614.
17.Bateman A, Martin M, Orchard S, Magrane M, Agivetova R, Ahmad S, Alpi E, Bowler-Barnett EH, Britto R, Bursteinas B, et al. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021; 49(D1):D480-D489.
18.Gene Help: Integrated Access to Genes of Genomes in the Reference Sequence Collection.
19.Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, Furlong LI. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2019.
20.Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Stein TI, Nudel R, Lieder I, Mazor Y, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Current Protocols in Bioinformatics. 2016; 54(1).
21.Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-2504.
22.Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021; 49(D1):D605-D612.
23.Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000; 28(1):235-242.
24.Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998; 114(4):842-845.
25.Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab. 2021; 23(5):1069-1083.
26.Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu Y, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-1321.
27.Papatheodoridi M, Cholongitas E. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Curr Pharm Des. 2018; 24(38):4574-4586.
28.Li Y, Qiao J, Wang B, Bai M, Shen J, Cheng Y. Paeoniflorin Ameliorates Fructose-Induced Insulin Resistance and Hepatic Steatosis by Activating LKB1/AMPK and AKT Pathways. Nutrients. 2018; 10(8):1024.
29.Ma Z, Chu L, Liu H, Wang W, Li J, Yao W, Yi J, Gao Y. Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats. Sci Rep-Uk. 2017; 7(1).
30.Jeong JW, Lee HH, Han MH, Kim GY, Hong SH, Park C, Choi YH. Ethanol extract of Poria cocos reduces the production of inflammatory mediators by suppressing the NF-kappaB signaling pathway in lipopolysaccharide-stimulated RAW 264.7 macrophages. BMC Complement Altern Med. 2014; 14:101.
31.Kim JH, Sim HA, Jung DY, Lim EY, Kim YT, Kim BJ, Jung MH. Poria cocus Wolf Extract Ameliorates Hepatic Steatosis through Regulation of Lipid Metabolism, Inhibition of ER Stress, and Activation of Autophagy via AMPK Activation. Int J Mol Sci. 2019; 20(19).
32.Gadde KM, Franciscy DM, Wagner HN, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003; 289(14):1820-1825.
33.Salameh TS, Mortell WG, Logsdon AF, Butterfield DA, Banks WA. Disruption of the hippocampal and hypothalamic blood–brain barrier in a diet-induced obese model of type II diabetes: prevention and treatment by the mitochondrial carbonic anhydrase inhibitor, topiramate. Fluids and Barriers of the CNS. 2019; 16(1).
34.Sun L, Wang Q, Liu M, Xu G, Yin H, Wang D, Xie F, Jin B, Jin Y, Yang H, et al. Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease. Endocrine. 2020; 69(2):294-302.
35.Sun L, Yin H, Liu M, Xu G, Zhou X, Ge P, Yang H, Mao Y. Impaired albumin function: a novel potential indicator for liver function damage? Ann Med. 2019; 51(7-8):333-344.
36.Basolo A, Ando T, Chang DC, Hollstein T, Krakoff J, Piaggi P, Votruba S. Reduced Albumin Concentration Predicts Weight Gain and Higher Ad Libitum Energy Intake in Humans. Front Endocrinol. 2021; 12.
37.Garcia Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology (Baltimore, Md.). 2013; 58(5):1836-1846.
38.Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017; 169(3):381-405.
39.Chao H, Chao S, Lin H, Ku H, Cheng C. Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2019; 20(2):298.
40.Cao Y, Sun W, Xu G. Fuzhu jiangtang granules combined with metformin reduces insulin resistance in skeletal muscle of diabetic rats via PI3K/Akt signaling. Pharm Biol. 2019; 57(1):660-668.
41.Fleischmann M, Iynedjian PB. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem J. 2000; 349(Pt 1):13-17.
42.Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends in Endocrinology & Metabolism. 2008; 19(2):65-73.
43.Ge Q, Chen L, Yuan Y, Liu L, Feng F, Lv P, Ma S, Chen K, Yao Q. Network Pharmacology-Based Dissection of the Anti-diabetic Mechanism of Lobelia chinensis. Front Pharmacol. 2020; 11.
44.Wang L, Liu X, Zhan S, Guo J, Yang S, Zhong T, Li L, Zhang H, Wang Y. Inhibition of GSK3beta Reduces Ectopic Lipid Accumulation and Induces Autophagy by the AMPK Pathway in Goat Muscle Satellite Cells. Cells-Basel. 2019; 8(11).
45.Eijkelenboom A, Burgering BMT. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Bio. 2013; 14(2):83-97.
46.Xiong X, Tao R, Depinho RA, Dong XC. The Autophagy-related Gene 14 (Atg14) Is Regulated by Forkhead Box O Transcription Factors and Circadian Rhythms and Plays a Critical Role in Hepatic Autophagy and Lipid Metabolism. J Biol Chem. 2012; 287(46):39107-39114.
47.Deng X, Zhang W, O-Sullivan I, Williams JB, Dong Q, Park EA, Raghow R, Unterman TG, Elam MB. FoxO1 inhibits sterol regulatory element-binding protein-1c (SREBP-1c) gene expression via transcription factors Sp1 and SREBP-1c. J Biol Chem. 2012; 287(24):20132-20143.
48.Hirota K, Sakamaki J, Ishida J, Shimamoto Y, Nishihara S, Kodama N, Ohta K, Yamamoto M, Tanimoto K, Fukamizu A. A combination of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation of glucokinase and glucose-6-phosphatase genes in response to fasting and feeding. J Biol Chem. 2008; 283(47):32432-32441.
49.Chackelevicius CM, Gambaro SE, Tiribelli C, Rosso N. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World J Gastroenterol. 2016; 22(41):9096-9103.
50.Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, Han X, Peng Y, Chen X, Shen L, et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol. 2011; 166(2):281-290.
51.Rolla S, Alchera E, Imarisio C, Bardina V, Valente G, Cappello P, Mombello C, Follenzi A, Novelli F, Carini R. The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice. Clin Sci (Lond). 2016; 130(3):193-203.
52.Feng S, Belwal T, Li L, Limwachiranon J, Liu X, Luo Z. Phytosterols and their derivatives: Potential health‐promoting uses against lipid metabolism and associated diseases, mechanism, and safety issues. Compr Rev Food Sci F. 2020; 19(4):1243-1267.
53.Chen Y, Zeng A, Luo Z, He S, Li C, Lin S, Lu Q. Advances on pharmacology of β⁃sitosterol. Journal of Guangdong Pharmaceutical University. 2021; 37(01):148-153.
54.Gumede NM, Lembede BW, Nkomozepi P, Brooksbank RL, Erlwanger KH, Chivandi E. beta-Sitosterol mitigates the development of high-fructose diet-induced nonalcoholic fatty liver disease in growing male Sprague-Dawley rats. Can J Physiol Pharmacol. 2020; 98(1):44-50.
55.Nagata S. Apoptosis and Clearance of Apoptotic Cells. Annu Rev Immunol. 2018; 36:489-517.
56.Thapaliya S, Wree A, Povero D, Inzaugarat ME, Berk M, Dixon L, Papouchado BG, Feldstein AE. Caspase 3 Inactivation Protects Against Hepatic Cell Death and Ameliorates Fibrogenesis in a Diet-Induced NASH Model. Digest Dis Sci. 2014; 59(6):1197-1206.
57.Marion-Letellier R, Savoye G, Ghosh S. Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol. 2016; 785:44-49.
58.Lin F, Xu L, Huang M, Deng B, Zhang W, Zeng Z, Yinzhi S. beta-Sitosterol Protects against Myocardial Ischemia/Reperfusion Injury via Targeting PPARgamma/NF-kappaB Signalling. Evid Based Complement Alternat Med. 2020; 2020:2679409.
59.Wu L, Guo C, Wu J. Therapeutic potential of PPARgamma natural agonists in liver diseases. J Cell Mol Med. 2020; 24(5):2736-2748.